MedTrace Logo

Ivabradine for Rate Control in Permanent Atrial Fibrillation

NCT03987204 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2021-07-02

No results posted yet for this study

Summary

Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibrillation and previously-implanted pacemakers.

Conditions

Interventions

DRUG

Ivabradine

Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Rachel Lampert, MD · Yale University

  • Hyon Jae Lee, MD · Yale New Haven Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-15
Primary Completion
2019-09-17
Completion
2019-09-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03987204 on ClinicalTrials.gov